News 89bio shows its NASH hand, boosting FGF21 concept Positive phase 2b results on liver fibrosis follow similar data with a rival drug from Akero.
Oncology Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treat... At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.
